Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 1.00 |
| ▸ | AKT2 | P31751 | 16/20 | 0.81 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5401310 | 1.00 | AKT1 (1.00) | AKT1AKT2AKT3TDP1RUVBL1 | |
| SCHEMBL5348455 | 0.90 | AKT1 (1.00) | AKT1AKT2AKT3TDP1RUVBL1 | |
| SCHEMBL29388417 | 0.89 | AKT1 (0.87) | AKT1AKT2AKT3TDP1RUVBL1 | |
| SCHEMBL5645940 | 0.89 | AKT1 (0.87) | AKT1AKT2AKT3TDP1RUVBL1 | |
| SCHEMBL5315633 | 0.88 | AKT1 (0.79) | AKT1AKT2AKT3 | |
| SCHEMBL5354357 | 0.86 | AKT1 (0.84) | AKT1AKT2AKT3 | |
| SCHEMBL5313477 | 0.86 | AKT1 (0.84) | AKT1AKT2AKT3TDP1RUVBL1 | |
| SCHEMBL14501032 | 0.86 | AKT1 (0.84) | AKT1AKT2AKT3TDP1RUVBL1 | |
| SCHEMBL1434365 | 0.85 | AKT1 (0.86) | AKT1AKT2AKT3TDP1RUVBL1 | |
| SCHEMBL12375868 | 0.84 | AKT1 (0.85) | AKT1AKT2AKT3TDP1RUVBL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | claimed |
| US-20050222155-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2005-10-06 | — | — | US | claimed |
| US-20040102360-A1 | Combination therapy | BARNETT STANLEY F (US) | 2004-05-27 | — | — | US | claimed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20060142178-A1 | Method of treating cancer | BARNETT STANLEY F | 2006-06-29 | — | — | US | disclosed |
| US-20050222155-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2005-10-06 | — | — | US | disclosed |
| EP-1496981-A2 | METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20040102360-A1 | Combination therapy | BARNETT STANLEY F (US) | 2004-05-27 | — | — | US | disclosed |
| WO-2003084473-A2 | METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222155-A1 | Inhibitors of akt activity | AKT1, AKT2, AKT3 | AKT1 1/4885AKT2 2/4885AKT3 3/4885 |
| US-20040102360-A1 | Combination therapy | MTOR, AKT2, PLK1 | AKT1 4/4885AKT2 2/4885AKT3 7/4885 |
| US-20060142178-A1 | Method of treating cancer | PACSIN2, CTTN, TNK2 | AKT1 13/4885AKT2 9/4885AKT3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.